No Data
Osecon: 2024 Annual Report Summary
Osecon: 2024 Annual Report
Osecon: Report for the first quarter of 2025
Beijing Aosaikang Pharmaceutical (002755.SZ): In the first quarter, net income was 54.7303 million yuan, an increase of 73.50% year-on-year.
On April 27, Gelonghui reported that Beijing Aosaikang Pharmaceutical (002755.SZ) announced its first quarter report for 2025, with revenue of 0.509 billion yuan, a year-on-year increase of 13.39%; net income attributable to shareholders of the listed company was 54.7303 million yuan, a year-on-year increase of 73.50%; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 43.9972 million yuan, a year-on-year increase of 86.93%; EPS was 0.06 yuan.
Beijing Aosaikang Pharmaceutical (002755.SZ) announced its first-quarter performance, with a net income of 54.7303 million yuan, a year-on-year increase of 73.50%.
Beijing Aosaikang Pharmaceutical (002755.SZ) released its first quarter report for 2025, in which the company achieved a revenue of 5...
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
